Resolute Onyx Zotarolimus-Eluting Coronary Stent System - RX and OTW; Onyx Frontier Zotarolimus-Eluting Coronary Stent S
Medtronic Vascular · Decision date Dec 19, 2025
What did the FDA decide?
FDA records P160043/S089 as a supplement to PMA P160043, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 19, 2025.
FDA approval order statement
automation of several handling and weighing steps
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Dec 19, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P160043/S089
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic Vascular
- Product code
- NIQ
- Decision code
- OK30
- Decision date
- Dec 19, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Coronary drug-eluting stent.
- Applicant
- Medtronic Vascular
- Product code
- NIQ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P160043. Subsequent supplements may change the device or its indications.
FDA decision timeline
P160043 · Original PMA
RESOLUTE ONYX ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM
P160043/S089 received
Application receipt date recorded by FDA.
P160043/S089 · FDA decision
30-Day Notice
P160043/S090 · Related supplement
Onyx Frontier Zotarolimus Eluting Coronary Stent System
P160043/S092 · Related supplement
Resolute Onyx Zotarolimus-Eluting Coronary Stent System; Onyx Frontier Zotarolimus-Eluting Coronary Stent System Stent S
P160043/S093 · Related supplement
RESOLUTE ONYX ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM
P160043/S094 · Related supplement
Resolute Onyx Zotarolimus-Eluting Coronary Stent System; Onyx Frontier Zotarolimus-Eluting Coronary Stent System Stent S
P160043/S095 · Related supplement
Resolute Onyx Zotarolimus-Eluting Coronary Stent System
P160043/S096 · Related supplement
Resolute Onyx Zotarolimus-Eluting Coronary Stent Systems
Timeline entries are records held by MedtechLedger for P160043. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160043
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Vascular | PMA approval | Apr 28, 2017 | FDA | |
| Medtronic Vascular | PMA supplement | Mar 25, 2026 | FDA | |
| Medtronic Vascular | PMA supplement | May 13, 2026 | FDA | |
| Medtronic Vascular | PMA supplement | May 29, 2026 | FDA | |
| Medtronic Vascular | PMA supplement | Jun 5, 2026 | FDA | |
| Medtronic Vascular | PMA supplement | Aug 14, 2026 | FDA | |
| Medtronic Vascular | PMA supplement | Oct 16, 2026 | FDA |
Explore the linked device profile
Other records with product code NIQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Abbott Vascular | PMA supplement | Oct 1, 2026 | FDA | |
ORSIRO Sirolimus Eluting Coronary Stent SystemP170030/S066 | Biotronik AG | PMA supplement | Sep 24, 2026 | FDA |
| Abbott Vascular | PMA supplement | Aug 28, 2026 | FDA | |
| BOSTON SCIENTIFIC CORPORATION | PMA supplement | Aug 21, 2026 | FDA | |
ORSIRO Sirolimus Eluting Coronary Stent SystemP170030/S065 | Biotronik AG | PMA supplement | Aug 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Vascular
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 3576 Unocal Pl., Santa Rosa, CA, 95403
Sources and methodology
- Original FDA record: P160043/S089
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records






